Compare ASPS & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPS | SER |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.5M | 56.4M |
| IPO Year | 2025 | 2024 |
| Metric | ASPS | SER |
|---|---|---|
| Price | $5.87 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 12.9K | ★ 49.6K |
| Earning Date | 10-29-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 112.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $942,213,000.00 | $130,000.00 |
| Revenue This Year | $16.74 | N/A |
| Revenue Next Year | $9.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 132.14 |
| 52 Week Low | $4.30 | $1.22 |
| 52 Week High | $10.31 | $4.45 |
| Indicator | ASPS | SER |
|---|---|---|
| Relative Strength Index (RSI) | 53.93 | 30.65 |
| Support Level | $5.20 | N/A |
| Resistance Level | $5.98 | $2.13 |
| Average True Range (ATR) | 0.47 | 0.30 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 67.01 | 17.02 |
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.